157 related articles for article (PubMed ID: 16527890)
1. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis.
de Fost M; Hollak CE; Groener JE; Aerts JM; Maas M; Poll LW; Wiersma MG; Häussinger D; Brett S; Brill N; vom Dahl S
Blood; 2006 Aug; 108(3):830-5. PubMed ID: 16527890
[TBL] [Abstract][Full Text] [Related]
2. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients.
Poll LW; Koch JA; Willers R; Aerts H; Scherer A; Häussinger D; Mödder U; vom Dahl S
Blood Cells Mol Dis; 2002; 28(2):209-20. PubMed ID: 12064917
[TBL] [Abstract][Full Text] [Related]
3. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
Grigorescu Sido P; Drugan C; Cret V; Al-Kzouz C; Denes C; Coldea C; Zimmermann A
J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
[TBL] [Abstract][Full Text] [Related]
4. Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy.
van Breemen MJ; de Fost M; Maas M; Wiersma MG; Hollak CE; Poll LW; Vom Dahl S; Boot RG; Aerts JM
J Inherit Metab Dis; 2009 Apr; 32(2):274-9. PubMed ID: 19255873
[TBL] [Abstract][Full Text] [Related]
5. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
6. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
Boomsma JM; van Dussen L; Wiersma MG; Groener JE; Aerts JM; Maas M; Hollak CE
Blood Cells Mol Dis; 2010 Mar; 44(3):181-7. PubMed ID: 20074983
[TBL] [Abstract][Full Text] [Related]
8. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT).
Czartoryska B; Tylki-Szymańska A; Górska D
Clin Biochem; 1998 Jul; 31(5):417-20. PubMed ID: 9721443
[TBL] [Abstract][Full Text] [Related]
9. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
10. Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data.
Raskovalova T; Deegan PB; Yang R; Pavlova E; Stirnemann J; Labarère J; Zimran A; Mistry PK; Berger M
Syst Rev; 2017 Apr; 6(1):87. PubMed ID: 28427477
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-sestamibi scintigraphy to monitor the long-term efficacy of enzyme replacement therapy on bone marrow infiltration in patients with Gaucher disease.
Erba PA; Minichilli F; Giona F; Linari S; Dambrosia J; Pierini A; Filocamo M; Di Rocco M; Buffoni F; Brady RO; Mariani G
J Nucl Med; 2013 Oct; 54(10):1717-24. PubMed ID: 23990684
[TBL] [Abstract][Full Text] [Related]
12. Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3.
Machaczka M; Kämpe Björkvall C; Wieremiejczyk J; Paucar Arce M; Myhr-Eriksson K; Klimkowska M; Hägglund H; Svenningsson P
Arch Immunol Ther Exp (Warsz); 2015 Feb; 63(1):65-71. PubMed ID: 25205209
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
Poll LW; Koch JA; vom Dahl S; Willers R; Scherer A; Boerner D; Niederau C; Häussinger D; Mödder U
Skeletal Radiol; 2001 Sep; 30(9):496-503. PubMed ID: 11587517
[TBL] [Abstract][Full Text] [Related]
15. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
Zimran A; Wang N; Ogg C; Crombez E; Cohn GM; Elstein D
Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
[TBL] [Abstract][Full Text] [Related]
16. Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia.
Benedik-Dolničar M; Kitanovski L
Pediatr Int; 2011 Dec; 53(6):1018-22. PubMed ID: 21883686
[TBL] [Abstract][Full Text] [Related]
17. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
18. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Angell J; Ross L; Puga AC; Peterschmitt JM
Blood Cells Mol Dis; 2014 Dec; 53(4):274-6. PubMed ID: 24835462
[TBL] [Abstract][Full Text] [Related]
19. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
Heitner R; Elstein D; Aerts J; Weely Sv; Zimran A
Blood Cells Mol Dis; 2002; 28(2):127-33. PubMed ID: 12064906
[TBL] [Abstract][Full Text] [Related]
20. Bone events and evolution of biologic markers in Gaucher disease before and during treatment.
Stirnemann J; Belmatoug N; Vincent C; Fain O; Fantin B; Mentré F
Arthritis Res Ther; 2010; 12(4):R156. PubMed ID: 20696071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
